No Conflicts or Debarment Sample Clauses
No Conflicts or Debarment. MSK will ensure that MSK, the Investigator-Sponsor, and other Study personnel, to the best of MSK’s knowledge: (a) are under no contractual obligation that would knowingly breach this Agreement; (b) do not have any undisclosed financial or other interest in Company or the outcome of the Study that would knowingly interfere with their independent judgment; (c) have not been, and are not under consideration to be (i) debarred from providing services pursuant to Section 306 of the United States Federal Food, Drug and Cosmetic Act 21 U.S.C. §335a; (ii) excluded, debarred or suspended from, or otherwise ineligible to participate in any federal or state health care programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. §1320a-7b(f)); (iii) disqualified by any government or regulatory agencies from performing specific services, and are not subject to a pending disqualification proceeding; or (iv) convicted of a criminal offense related to the provision of health care items or services. During each Study, to the extent permitted by law, MSK will notify Company immediately if MSK, the Investigator-Sponsor, and any other Study personnel are subject to the foregoing.
No Conflicts or Debarment. Institution will use reasonable efforts to ensure that neither Institution nor any personnel participating in the Study (a) are under any contractual or other obligations or restrictions which are inconsistent with Institution’s obligations under this Agreement, (b) have a financial or other interest in Sponsor or the outcome of the Study which might interfere with their independent judgment, or (c) have been debarred, or are known to be under consideration to be debarred, by the United States Food and Drug Administration (the “FDA”) from working in, or providing services to, any pharmaceutical, medical device or biotechnology company. Institution has obtained and will maintain all authorizations and permits required by law for Institution to conduct the Study under this Agreement. Bezkonfliktnost nebo neexistence zákazu činnosti. Zdravotnické zařízení vyvine rozumné úsilí k zajištění toho, že ani zdravotnické zařízení, ani personál, který se na studii podílí, (a) nemají žádný smluvní ani jiný závazek nebo omezení, která jsou v rozporu s povinnostmi zdravotnického zařízení podle této smlouvy, (b) nemají finanční ani jiný zájem na zadavateli nebo výsledku studie, který by mohl být v rozporu s jejich nezávislým úsudkem, nebo (c) jim nebyla zakázána činnost a ani mu není známo, že by se ze strany amerického Úřadu pro potraviny a léky (dále jen „FDA“) u nich uvažovalo o zákazu práce nebo poskytování služeb pro jakoukoli farmaceutickou nebo biotechnologickou společnost nebo společnost vyrábějící zdravotnické prostředky. Zdravotnické zařízení získalo a bude zachovávat všechna oprávnění a povolení, která jsou zákonem požadována pro provádění studie podle této smlouvy.
No Conflicts or Debarment. Institution will ensure that Institution, its trustees, officers and directors, Investigator, Participating Site(s), Sub-investigator(s), and Study Personnel: (a) are under no contractual or other obligation or restriction that is inconsistent with Institution’s and Investigator’s performance of or obligations under this Agreement; and (b) do not have a financial or other interest in GSK or LIXTE or the outcome of the Study that might interfere with their independent judgment. Institution will ensure that Institution, the Study Personnel and any and all Participating Site(s), and GSK and LIXTE, respectively, will ensure that it and any of its personnel who access Institution’s facilities, premises, or systems under this Agreement have not been, and are not under consideration to be (i) debarred from providing services pursuant to Section 306 of the United States Federal Food, Drug and Cosmetic Act 21 U.S.C. § 335a; (ii) excluded, debarred or suspended from, or otherwise ineligible to participate in any federal or state health care programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. § 1320a-7b(f)); (iii) disqualified by any government or regulatory agencies from performing specific services, and are not subject to a pending disqualification proceeding; or (iv) convicted of a criminal offense related to the provision of health care items or services, or under investigation or subject to any such action that is pending. During the Study and for a period of two (2) years following completion or early termination of the Study, each Party will notify the other Parties promptly if such party or any of its personnel involved in the conduct of the Study (or in the case of GSK and LIXTE any of their respective personnel who access Institution’s facilities, premises, or systems under this Agreement) are subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of such Party’s knowledge, is threatened.
No Conflicts or Debarment. Institution will use reasonable efforts to ensure that neither Investigator nor, if known, any personnel participating in the Study (a) are under any contractual or other obligations or restrictions which hinder the performance of Institution’s and Investigator’s obligations under this Agreement, (b) have a financial or other interest in Sponsor or the outcome of the Study which might interfere with their independent judgment, or (c) have been debarred, or are under consideration to be debarred, by the United States Food and Drug Administration (the “FDA”) from working in, or providing services to, any pharmaceutical, medical device or biotechnology company. Institution has obtained and will maintain all authorizations and permits required by Applicable Law for Institution and Investigator to conduct the Study under this Agreement.
No Conflicts or Debarment. Institution will use reasonable efforts to ensure that neither Investigator nor any personnel participating in the Study (a) are under any contractual or other obligations or restrictions which are inconsistent with Institution’s and Investigator’s obligations under this Agreement, (b) have a financial or other interest in Sponsor or the outcome of the Study which might interfere with their independent judgment, or (c) have been debarred, or are under consideration to be debarred, by the United States Food and Drug Administration (the “FDA”) from nemocnice Plzeň, Neurochirurgická klinika, alej Svobody 80, 304 60 Plzeň Zdravotnické zařízení a zkoušející budou provádět studii kompetentním způsobem, v souladu s vysokými vědeckými a profesionálními normami, budou se striktně řídit protokolem, touto smlouvou a pokyny zadavatele a ▇▇▇ pověřených osob, přičemž zdravotnické zařízení ani zkoušející nebudou používat hodnocené zařízení k žádným jiným účelům. Zdravotnické zařízení a zkoušející budou dodržovat veškeré příslušné zákony, směrnice a doporučení v místě, kde se studie provádí, což zahrnuje mimo jiné směrnice Mezinárodní rady pro harmonizaci technických požadavků týkajících se humánních léčivých přípravků, správnou klinickou praxi (tzv. „ICH/GCP“) a veškeré další platné zákony a směrnice týkající se ochrany osobních údajů. Zdravotnické zařízení a zkoušející uplatnili a uzavřeli se zaměstnanci a/nebo vybranými poskytovateli služeb z řad třetích stran náležité smlouvy týkající se použití, zpracování a předávání osobních údajů v souladu s nařízením Evropské unie o ochraně fyzických osob v souvislosti se zpracováním osobních údajů a o volném pohybu těchto údajů (tzv. GDPR).